Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.5.2013

ALDH1 in Combination with CD44 as Putative Cancer Stem Cell Markers are Correlated with Poor Prognosis in Urothelial Carcinoma of the Urinary Bladder  

Keymoosi, Hossein (Department Pathology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences)
Gheytanchi, Elmira (Oncopatholgy Research Centre, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences)
Asgari, Mojgan (Department Pathology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences)
Shariftabrizi, Ahmad (Department of Pathology, Tufts University School of Medicine)
Madjd, Zahra (Department Pathology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.5, 2014 , pp. 2013-2020 More about this Journal
Abstract
Background: The aldehyde dehydrogenase 1 family member A1 (ALDH1A1) is one of the promising markers for identifying cancer stem cells in many cancer types, along with other markers including CD44. The aim of the present study was to evaluate the expression and clinical significance of putative cancer stem cell markers, CD44 and ALDH1A1, in a series of urothelial carcinomas of urinary bladder (UCUB) by tissue microarray (TMA). Materials and Methods: A total of 159 Urothelial Carcinomas (UC) including 96 (60%) low grade and 63 (40%) high grade carcinomas were immunohistochemically examined for the expression of CD44 and ALDH1A1. Correlations of the relative expression of these markers with clinicopathological parameters were also assessed. Results: High level expression of ALDH1A1 was found in 16% (25/159) of bladder UC which was significantly correlated with increased tumor size (p value=0.002), high grade (p value<0.001), pathologic stage (T1, p value=0.007 and T2, p value<0.001) and increased rate of recurrence (p value=0.013). A high level of CD44 expression was found in 43% (68/159) of cases, being positively correlated with histologic grade (p value=0.032) and recurrence (p value=0.039). Conclusions: Taken together, our results showed that ALDH1 was concurrently expressed in a fraction of CD44+ tumors and its expression correlated with poor prognosis in UCs. ALDH1A1 could be an ideal marker for targeted therapy of UCs in combination with conventional therapies, particularly in patients with high grade carcinomas. These findings indicate that cells expressing ALDH1A1 along with CD44 can be a potential therapeutic target in bladder carcinomas.
Keywords
ALDH1A1; CD44; TMA; bladder carcinoma; targeted therapy;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Clarke MF, Dick JE, Dirks PB, et al (2006). Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res, 66, 9339-44.   DOI   ScienceOn
2 Clay MR, Tabor M, Owen JH, et al (2010). Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck, 32, 1195-201.   DOI
3 Cordon-Cardo C, Zhang ZF, Dalbagni G, et al (1997). Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res, 57, 1217-21.
4 Deng S, Yang X, Lassus H, et al (2010). Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One, 5, 10277.   DOI
5 Dwyer RM, Potter-Beirne SM, Harrington KA, et al (2007). Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res, 13, 5020-7.   DOI   ScienceOn
6 Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.   DOI   ScienceOn
7 Ferris J, Berbel O, Alonso-Lopez J, Garcia J, Ortega JA (2013). Environmental non-occupational risk factors associated with bladder cancer. Acta Urol Esp, 37, 579-86.
8 Ginestier C, Hur MH, Charafe-Jauffret E, et al (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1, 555-67.   DOI   ScienceOn
9 Grignon DJ (2009). The current classification of urothelial neoplasms. Mod Pathol, 22, 60-9.   DOI
10 Brandt WD, Matsui W, Rosenberg JE, et al (2009). Urothelial carcinoma: stem cells on the edge. Cancer Metastasis Rev, 28, 291-304.   DOI
11 Billerey C, Chopin D, Aubriot-Lorton MH, et al (2001). Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol, 158, 1955-59.   DOI
12 Bohl SR, Pircher A, Hilbe W (2011) Cancer stem cells: characteristics and their potential role for new therapeutic strategies. Onkologie, 34, 269-74.   DOI
13 Camp RL, Charette LA, Rimm DL (2000). Validation of tissue microarray technology in breast carcinoma. Lab Invest, 80, 1943-9.   DOI   ScienceOn
14 Chan KS, Espinosa I, Chao M, et al (2009). Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A, 106, 14016-21.   DOI   ScienceOn
15 Chan KS, Volkmer JP, Weissman I (2010). Cancer stem cells in bladder cancer: a revisited and evolving concept. Curr Opin Urol, 20, 393-97.   DOI
16 Chang CC, Shieh GS, Wu P, et al (2008). Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. Cancer Res, 68, 6281-91.   DOI   ScienceOn
17 Cheng LR, Montironi R, Davidson DD, Lopez-Beltran A, et al (2009). Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol, 22, 70-95.   DOI
18 Choi D, Lee HW, Hur KY, et al (2009). Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol, 15, 2258-64.   DOI
19 Ahmad MR, Pervaiz MK, Pervaiz (2012). Non-occupational risk factors of urinary bladder cancer in Faisalabad and Lahore, Pakistan. J Pak Med Assoc, 62, 236-39.
20 Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 100, 3983-8.   DOI   ScienceOn
21 Balicki D (2007). Moving Forward in Human Mammary Stem Cell Biology and Breast Cancer Prognostication Using ALDH1. Cell Stem Cell, 1, 485-7.   DOI
22 Bao S, Wu Q, McLendon RE, et al (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756-60.   DOI   ScienceOn
23 Bentivegna A, Conconi D, Panzeri E, et al (2010). Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples. Cancer Sci, 101, 416-24.   DOI   ScienceOn
24 Yang YM, Chang JW (2008). Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest, 26, 725-33.   DOI
25 Wielenga VJ, Heider KH, Offerhaus GJ, et al (1993). Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res, 53, 4754-6.
26 Woodman AC, Sugiyama M, Yoshida K et al (1996). Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol, 149, 1519-30.
27 Wu XR (2005). Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer, 5, 713-25.   DOI   ScienceOn
28 Zhang AM, Fan Y, Yao Q, et al (2012). Identification of a cancer stem-like population in the Lewis lung cancer cell line. Asian Pac J Cancer Prev, 13, 761-66.   과학기술학회마을   DOI   ScienceOn
29 Slomiany MG, Dai L, Tolliver LB, et al (2009). Inhibition of Functional Hyaluronan-CD44 Interactions in CD133-positive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides. Clin Cancer Res, 15, 7593-601.   DOI
30 Reya T, Morrison SJ, Clarke MF, Weissman IL (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105-11.   DOI   ScienceOn
31 Salehi A, Khezri AA, Malekmakan L, Aminsharifi A (2011). Epidemiologic status of bladder cancer in Shiraz, southern Iran. Asian Pac J Cancer Prev, 12, 1323-27.
32 Satpute PS, Hazarey V, Ahmed R, Yadav L (2013). Cancer stem cells in head and neck squamous cell carcinoma: a review. Asian Pac J Cancer Prev, 14, 5579-87.   과학기술학회마을   DOI
33 Su Y, Qiu Q, Zhang X, et al (2010). Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev, 19, 327-37.   DOI
34 Taeb J, Asgari M, Abolhasani M, Farajollahi MM, Madjd Z (2014). Expression of prostate stem cell antigen (PSCA) in prostate cancer: A tissue microarray study of Iranian patients. Pathol Res Pract, 210, 18-23.   DOI   ScienceOn
35 Tanei T, Morimoto K, Shimazu K, et al (2009). Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res, 15, 4234-41.   DOI   ScienceOn
36 Urakami S, Shiina H, Enokida H, et al (2006). Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/betacatenin signaling pathway. Clin Cancer Res, 12, 383-91.   DOI
37 van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH (2002). Frequent FGFR3 mutations in urothelial papilloma. J Pathol, 198, 245-51.   DOI
38 Mehrazma M, Madjd Z, Kalantari E, et al. (2013). Expression of Stem Cell Markers, CD133 and CD44, in Pediatric Solid Tumors: A Study Using Tissue Microarray. Fetal Pediatr Pathol, 32, 192-204.   DOI   ScienceOn
39 Luo Y, Cui XH, Jiang YG, et al (2012). Sorting and identification of cancer stem cells in human prostate cancer cell lines. Zhonghua Nan Ke Xue, 18, 1062-8.
40 Madjd Z, Gheytanchi E, Erfani E, Asadi-Lari M (2013). Application of stem cells in targeted therapy of breast cancer: a systematic review. Asian Pac J Cancer Prev, 14, 2789-800.   과학기술학회마을   DOI
41 McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS, Sr (1985). Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med, 109, 716-21.
42 Mohsenzadegan M, Madjd Z, Asgari M, et al (2013). Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis. Cancer Immunol Immunother, 62, 1609-18.   DOI   ScienceOn
43 Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV (2008). Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol, 18, 260-67.   DOI   ScienceOn
44 Overdevest JB, Thomas S, Kristiansen G, et al (2011). CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res, 71, 3802-11.   DOI
45 Pearce DJ, Taussig D, Simpson C, et al (2005). Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells, 23, 752-60.   DOI   ScienceOn
46 Rasheed ZA, Yang J, Wang Q, et al (2010). Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst, 102, 340-51.   DOI
47 Li T, Su Y, Mei Y, et al (2010). ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest, 90, 234-44.   DOI
48 Kim YJ, Yoon HY, Kim JS, et al (2013). HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling. Int J Cancer, 133, 1135-42.   DOI
49 Komuro H, Saihara R, Shinya M, et al (2007). Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines. J Pediatr Surg, 42, 2040-5.   DOI
50 Kononen J, Bubendorf L, Kallioniemi A, et al (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med, 4, 844-7.   DOI   ScienceOn
51 Lee HJ, Choe G, Jheon S, et al (2010). CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. J Thorac Oncol, 5, 649-57.
52 Li X, Lewis MT, Huang J, et al (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst, 100, 672-9.   DOI   ScienceOn
53 Lingala S, Cui YY, Chen X, et al (2010). Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol, 89, 27-35.   DOI
54 Liu DY, Ren CP, Yuan XR, et al (2012). ALDH1 expression is correlated with pathologic grade and poor clinical outcome in patients with astrocytoma. J Clin Neurosci, 19, 1700-5.   DOI
55 Lugli A, Iezzi G, Hostettler I, et al (2010). Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer, 103, 382-90.   DOI
56 Ho PL, Kurtova A, Chan KS (2012). Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol, 9, 583-94.   DOI
57 Hatina J, Schulz WA (2012). Stem cells in the biology of normal urothelium and urothelial carcinoma. Neoplasma, 59, 728-36.   DOI
58 He X, Marchionni L, Hansel DE, et al (2009). Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells, 27, 1487-95.   DOI
59 Heppner GH (1984). Tumor heterogeneity. Cancer Res, 44, 2259-65.
60 Huang EH, Hynes MJ, Zhang T, et al (2009). Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res, 69, 3382-9.   DOI   ScienceOn
61 Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A (2008). Expression of the “stem cell marker” CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer, 8, 48.   DOI
62 Immervoll H, Hoem D, Steffensen OJ, Miletic H, Molven A (2011). Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers. J Histochem Cytochem, 59, 441-55.   DOI
63 Jaggupilli A, Elkord E (2012). Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol, 2012, 1-11.
64 Jiang F, Qiu Q, Khanna A, et al (2009). Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res, 7, 330-8.   DOI
65 Jordan CT, Guzman ML, Noble M (2006). Cancer stem cells. N Engl J Med, 355, 1253-61.   DOI   ScienceOn
66 Cote RJ, Dunn MD, Chatterjee SJ, et al (1998). Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res, 58, 1090-4.
67 Black WJ, Stagos D, Marchitti SA, et al (2009). Human aldehyde dehydrogenase genes: alternatively spliced transcriptional variants and their suggested nomenclature. Pharmacogenet Genomics, 19, 893-902.   DOI